Analysis of the characteristics and influencing factors of HBsAg change in chronic hepatitis B patients treated with NAs
-
1.
Department of Infectious Diseases, The First Affiliated Hospital of Bengbu Medical College, Bengbu Anhui 233004
-
2.
The Fifth Medical Center, The People's Liberation Army General Hospital, Beijing 100039, China
-
Corresponding author:
ZHAO Shou-song, 13955215571@139.com
-
Received Date:
2019-02-15
Accepted Date:
2019-04-20
-
Abstract
ObjectiveTo observe the dynamic change of HBsAg serum level in chronic hepatitis B(CHB) patients treated with NAs for HBVDNA negative conversion, compare the change of HBsAg between HBeAg-positive and HBeAg-negative patients, estimate the time of HBsAg clearance, and explore the possible course of CHB treated with NAs.MethodsThe quantitation of HBsAg in patients treated with NA HBVDNA negative conversion was set as the baseline value, the dynamic change of HBsAg levels were observed after 6 months, 1 year, 3 years, 5 years and 7 years of HBVDNA negative conversion, and the difference of HBsAg quantification between HBeAg(+) group and HBeAg(-) group was compared.ResultsAmong 109 HBeAg-positive patients, the mean levels of HBsAg after 6 months, 1 year, 3 years, 5 years and 7 years of HBVDNA negative conversion were 3.347, 3.329, 3.107, 3.169, 2.960 and 2.164 log10IU/mL, respectively.Among 116 HBeAg-negative patients, the mean levels of HBsAg after 6 months, 1 year, 3 years, 5 years and 7 years of HBVDNA negative conversion were 3.133, 3.193, 2.970, 2.967, 2.536 and 2.083 log10IU/mL, respectively.After NAs treatment, the HBsAg levels in HBeAg-positive and HBeAg-negative patients showed a decreasing trend of fluctuation at 6 months, 1 year, 3 years, 5 years and 7 years after HBVDNA negative conversion(P < 0.01).According to the linear regression equation fitted by the quantitative decline trend of HBsAg, the HBsAg clearance time in HBeAg positive group and HBeAg negative group were calculated to be 25 years and 22 years, respectively.ConclusionsAmong the CHB treated with NAs, the clearance time of HBsAg in HBeAg positive group and HBeAg negative group will take more than 20 years in theory.Therefore, the treatment of CHB with NAs requires a long course of treatment.
-
-
References
[1]
|
WANG FS, FAN JG, ZHANG Z, et al.The global burden of liver disease:the major impact of China[J].Hepatology, 2014, 60(6):2099. doi: 10.1002/hep.v60.6 |
[2]
|
LIANG TJ, BLOCK TM, MCMAHON BJ, et al.Present and future therapies of hepatitis B:from discovery to cure[J].Hepatology, 2015, 62(6):1893. doi: 10.1002/hep.28025 |
[3]
|
王贵强, 王福生, 成军, 等.慢性乙型肝炎防治指南(2015年更新版)[J].临床肝胆病杂志, 2015, 31(12):1941. doi: 10.3969/j.issn.1001-5256.2015.12.002 |
[4]
|
陈嵬, 吴峰, 窦晓光, 等.慢性HBV感染者肝脏HBV cccDNA含量相关因素分析[J].临床肝胆病杂志, 2013, 29(6):434. doi: 10.3969/j.issn.1001-5256.2013.06.011 |
[5]
|
MAYNARD M, PARVAZ P, DURANTEL S, et al.Sustained HBs seroconversion during lamivudine and adefovir dipovoxil combination therapy for lamivudine failure[J].Hepatol, 2005, 42(2):279. doi: 10.1016/j.jhep.2004.09.017 |
[6]
|
BOGLIONE L, CARDELLINO CS, DE NICOLÒ A, et al.Different HBsAg decline after 3 years of therapy with entecavir in patients affected by chronic hepatitis B HBeAg-negative and genotype A, D and E[J].J Med Virol, 2014, 86(11):1845. doi: 10.1002/jmv.v86.11 |
[7]
|
ZENG LY, LIAN JS, CHEN JY, et al.Hepatitis B surface antigen levels during natural history of chronic hepatitis B:a Chinese perspective study[J].World J Gastroenterol, 2014, 20(27):9178. |
[8]
|
钮志林, 朱翔, 沈伟强.干扰素对慢性乙型肝炎病人肝细胞内HBV cccDNA、血清HBsAg、HBV-DNA的影响研究[J].中华医院感染学杂志, 2014, 24(4):792. |
[9]
|
肖作汉, 孟冈, 王立志.HBsAg定量对HBeAg阴性病人PEG-IFN治疗应答的预测[J].肝脏, 2014, 19(12):949. doi: 10.3969/j.issn.1008-1704.2014.12.013 |
[10]
|
陶晨, 叶伟, 赵伟.聚乙二醇干扰素对普通干扰素治疗失败慢性乙型肝炎病人的疗效[J].江苏医药, 2012, 38(23):2864. |
[11]
|
LI MH, ZHANG L, QU XJ, et al.Kinetics of hepatitis B surface antigen level in chronic hepatitis B patients who achieved hepatitis B surface antigen loss during pegylated interferon α-2a treatment[J].Chin Med J (Engl), 2017, 130(5):559. doi: 10.4103/0366-6999.200554 |
[12]
|
SETO WK, LAM YF, FUNG J, et al.Changes of HBsAg and HBV DNA levels in Chinese chronic hepatitis B patients after 5 years of entecavir treatment[J].J Gastroenterol Hepatol, 2014, 29(5):1028. doi: 10.1111/jgh.12476 |
[13]
|
QIU YW, HUANG LH, YANG WL, et al.Hepatitis B surface antigen quantification at hepatitis B e antigen seroconversion predicts virological relapse after the cessation of entecavir treatment in hepatitis B e antigen-positive patients[J].Int J Infect Dis, 2016, 43:43. doi: 10.1016/j.ijid.2015.10.019 |
[14]
|
LIANG Y, JIANG J, SU M, et al.Predictors of relapse in chronic hepatitis B after discontinuation of antiviral therapy[J].Aliment Pharmacol Ther, 2011, 34(3):344. doi: 10.1111/apt.2011.34.issue-3 |
-
-
Proportional views
-